Information for healthcare professionals
Ozempic®. For adults with type 2 diabetes to improve glycemic control, when diet and exercise plus maximal tolerated metformin dose alone do not achieve adequate glycemic control.
Indications and clinical use:
Ozempic® is indicated for the once weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with:
Not a substitute for insulin. Not for use in type 1 diabetes or for the treatment of diabetic ketoacidosis. Ozempic® is not indicated for use in pediatric patients.
Most serious warnings and precautions:
Risk of thyroid C-cell tumours: In both genders of rats and mice, semaglutide causes treatment-dependent thyroid C-cell tumours. Patients should be counselled regarding the risk and symptoms of thyroid tumours.
Other relevant warnings and precautions:
For more information:
Please consult the Product Monograph at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this advertisement.
The Product Monograph is also available by calling us at 1-800-465-4334.